The External Quality Assessment Scheme (EQAS) for Blood Screening Serology aims to raise standards and assess the phases of laboratory testing of blood units.
INTRODUCTION
The EQAS for Blood Screening Serology provided by the Transfusion Transmissible Infections -National Reference Laboratory (TTI-NRL) of the Research Institute for Tropical Medicine aims to raise standards and assess the phases of laboratory testing on blood units to determine inter-laboratory comparison. The NRL-Australia cites the importance of EQAS as this provides objective evidence of quality through its capability to: (1) review kit and assay performance through monitoring consistency and accuracy of test results, (2) check on lab performance through comparison of different laboratory data, (3) identify random and systematic errors that needs to be managed, and (4) identification of laboratory's training needs. 1 The EQAS panel is designed to check the capacity of a Blood Screening Facility (BSF) to detect the 5 common TTI. Samples of known reactivity to HIV, HBV, HCV, Syphilis and Malaria are to be tested in the same way as how a blood is routinely screened in the BSF as this mimics the routine samples received and screened. This allows the NRL and the participant to check and validate the blood unit screening process from receipt of samples up to release of results. 
RESULTS AND DISCUSSION
The predominant testing platform used by most participants was ChLIA followed by EIA, which is in concordance with what is being recommended by DOH DC No. 2013-0132. A significant number of participants are also using Rapid Diagnostic Test (RDT) kits for screening, which is not recommended for blood screening for the reason that these tests are often not as sensitive as EIA or instrument-based tests and can lead to false negative results in samples with low titres. 3 One participant used an expired reagent for testing one analyte and 10 participants failed to indicate the expiry dates of their assay reagent kits. Six participants were identified to have reported results that were due to data entry error or clerical error (e.g. reactive test results were interpreted as negative or vice versa). Table 1 . These aberrant results were either due to data entry errors, sample mix-up or sample carry-over (particularly where an instrument was used in assay set-up). In testing the HVHT4320 initial panel, these criteria must be met for a BSF to be classified as having an unsatisfactory performance: (a) At least one false negative result; (b) At least twenty percent (20%) false positive results. In accordance with these criteria, corresponding BSF, were given an investigation checklist to assist them in identifying their errors and make the necessary
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Panel Composition
The serology EQAS panel for program code HVHT4320 consists of twenty (20) pooled plasma samples obtained from blood donors from different regions of the country. Each pooled sample was prepared by mixing similar volumes of at least two samples that had similar antibody and antigen profiles. All samples were subjected to filtration prior to aliquoting. The samples were aliquoted and their homogeneity confirmed. Representative samples were tested following shipment to participants to confirm their stability. The serology profile for HIV, HBV, HCV, Syphilis of each sample were identified using Chemiluminiscensce (ChLIA), Enzyme Immunoassay (EIA), Rapid Plasma Reagin (RPR), Particle Agglutination (PA) and Western Blot (WB).
Program code MLRA415 consists of five (5) 
Participants
The Multimarker Blood Serology EQAS panel ID HVHT4320 and Malaria Microscopy EQAS Panel ID MLRA415 were distributed to 147 participants nationwide. These participants enrolled for the EQAS 2015 Program with a corresponding registration fee to cover expenses for the test event.
Majority of the participants are private institutions followed closely by government institutions and the remainders are from the Philippine Red Cross. Figure 1 shows the distribution of BSF by region. 
Data Analysis
For data analysis, the TTI-NRL made use of the online informatics system (OASYS) developed and operated by Oneworld Accuracy Systems, Canada.
Participants were asked to enter assay results as well as assay interpretations in the online informatics system. Results reported by participating BSF for assay interpretations and final status were compared with the relevant reference results for qualitative evaluation. An assay interpretation that is different from the reference result is marked as aberrant. The use of RDT kits for blood screening is of inadequate sensitivity compared to Enzyme Immunoassay or instrument-based tests. This can lead to false negative results in samples with low levels of the transfusion transmissible infection. BSFs using two platforms for screening are encouraged not to retest samples on kits of low specificity/sensitivity (e.g. initial screening on EIA or CLIA and retesting on RDT).
The Blood Screening Serology EQAS plays a vital role in the improvement of efficiency of BSFs that ultimately improves the overall quality of the National Blood Program. Active participation of BSFs in this EQAS program will positively strengthen the quality of their service as there will always be room for improvement and development in this system.
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Due to lack of accessibility to a good amount of inexpensive positive malaria blood samples, the NRL opted to provide a set of Blood Smears of known Malaria status to assess the capacity of the BSF to detect the presence of malaria parasite (qualitative identification only indicating presence or absence of the parasite). Although most, if not all, of the BSF perform platforms such as EIA and RDT for Malaria testing, it must be noted that according to DOH DC No. 2013-0132, a BSF should have the minimum capacity to detect the presence of malaria parasite through its gold standard, Malaria Microscopy. Presently, Malaria EIA kits in the country are neither evaluated nor regulated. The NRL for Malaria and other Parasites is in the process of evaluating these kits in partnership with the TTI-NRL. The microscopic diagnosis technique remains the gold standard for laboratory confirmation of malaria. 4 For the MLRA415 panel, 12% of participants reported aberrant results and out of these, 9% reported false detection of human Plasmodia and 3% reported having false negative slides. This may be attributed to the fact that technicians are not proficient in reading malaria smears. As an added quality assurance activity, the TTI-NRL conducts site-visits and assessment to BSF that attained satisfactory results and below. A detailed summary report and necessary recommendations are given to the BSF and the DOH for necessary actions.
less than 100% acceptable results on retesting of second panel (in comparison wi reference result, there is at least one false negative or at least 10% false positive r reported); or had an aberrant result in the initial panel that is due to clerical error whi BSF failed to identify upon run through of the EQAS Investigation Checklist. 
